SAGES 2007 Postgraduate Courses
MIS & Cancer Postgraduate Course
SAGES’ Debate on Controversies in G.I. Cancer Surgery:
“Now that we’ve been doing it, what is the evidence-based data to support it?”
Thursday, April 19, 2007
7:00 AM - 5:15 PM
* Included in Registration SuperPass (Option A) or Registration Option B.
Chair: Steven Brower, MD, Co-Chair: Nancy Baxter, MD, PhD
The 2007 SAGES Post Graduate Course “SAGES’ 1st Annual Debate on Controversies in GI Cancer Surgery” is designed for surgeons and endoscopists interested in gastrointestinal malignancies to identify the major controversies between open and minimally invasive surgery for GI cancer. Leading experts in the field of foregut, colorectal, hepatobiliary, and endocrine surgery will contrast in debate form the major controversies between open and MIS surgery for GI malignancies. The structure of the course will allow each expert to present the most up-to-date support for recommendation of either minimally invasive or open surgery, as well as panel discussions that will involve audience participation. The debate will examine the most important topics contrasting technical considerations in esophageal, gastric, pancreatic, hepatic, colorectal, and adrenal (adult and pediatric) neoplasms. Specific topics that will be debated include: immunologic differences between open and MIS cancer, perioperative morbidity and mortality for MIS versus open GI cancer surgery, role of perioperative staging for esophageal and gastric cancer, the approach for the curative treatment of esophageal cancer, MIS versus radical open surgery for gastric carcinoma, the appropriate staging of pancreatic carcinoma, optimal palliative approach to pancreatic carcinoma, the role of MIS in the treatment of pancreatic neuroendocrine tumors, current controversies in laparoscopic surgery for colona and rectal cancer, the appropriate role of MIS versus open surgery in hepatic neoplasms, and the role of MIS resections for pediatric adrenal tumors.
Objectives:
At the conclusion of this session, participants will be able to:
- Discuss the current optimal endoscopic and surgical treatments for primary and metastatic GI malignancies.
- Describe the outcomes for patients undergoing MIS or open surgery for GI malignancies with respect to perioperative management and morbidity.
- Relate the major controversies for the perioperative staging and surgical approach for the curative treatment of gastrointestinal malignancies.
- Understand the technical differences (if any) between MIS versus open surgery for GI malignancies.
- Determine the viability of minimally invasive surgical techniques for specific gastrointestinal malignancies
| Schedule | ||
|---|---|---|
| 7:00 AM | Introduction | Steven Brower, MD |
| The Controversy: Are there meaningful immunologic differences between open and MIS Cancer Surgery? | ||
| 7:15 AM | PRO: Immunosuppression in Open Oncological Surgery: Not a Problem | TBA |
| 7:30 AM | CON: Laparoscopic Surgery for Cancer Reduces Adverse Immunologic Sequelae | Richard L. Whelan, MD |
| The Controversy: Does MIS Surgery have advantages for perioperative management of cancer patients? | ||
| 7:45 AM | PRO: Perioperative Complications and LOS are Reduced for MIS Cancer Surgery | Christopher Schlachta, MD |
| 8:00 AM | CON: Perioperative Complications and LOS Equivalent for Open and MIS Cancer | Henrik Kehlet, MD |
| The Controversy: What is the role of perioperative staging for esophageal and gastric cancer? | ||
| 8:15 AM | PRO: EUS and MIS Staging Play an Integral Role in the Management of Primary Esophageal and Gastric Cancer | Jeffrey Ponsky, MD |
| 8:30 AM | CON: Preoperative Staging May Not Alter the Management of Primary Esophageal and Gastric Cancer | Mitchell Posner, MD |
| The Controversy: Is MIS an accepted approach for curative treatment of esophageal cancer? | ||
| 8:45 AM | PRO: 3 Field Radical Open Esophagogastrectomy is the Treatment of Choice
for Esophageal Cancer |
Steven De Meester, MD |
| 9:00 AM | CON: Total MIS Esophagectomy is the Treatment of Choice for Esophageal Cancer |
James D. Luketich, MD |
| 9:15 AM | Break | |
| The Controversy: Do all patients with curable gastric cancer require radical open resection? | ||
| 9:30 AM | PRO: Open Regional D2 Lymphadenectomy is Standard of Care for all Patients with Curable Gastric Carcinoma | Martin Karpeh, MD |
| 9:45 AM | CON: MIS approaches (Endomucosal Resection, Laparoscopic Gastrectomy, and Sentinel Node) are Appropriate for Selected Patients with Curable Gastric Cancer | Masahiro Ohgami, MD |
| 10:00 AM | Q & A | |
| The Controversy: Is laparoscopic staging standard of care for pancreatic cancer? | ||
| 10:15 AM | PRO: Laparoscopic Staging Should be Performed in All Patients Undergoing Pancreatic Cancer Surgery | Kevin Conlon, MD |
| 10:30 AM | CON: Current Preoperative Imaging is Adequate Staging for Patients Undergoing Pancreatic Cancer Surgery | Charles Yeo, MD |
| The Controversy: What is the best palliation of patients with pancreatic cancer? | ||
| 10:45 AM | PRO: Stent and/or Lap Bypass is the Procedure of Choice for Palliation of Pancreatic Carcinoma | Raul Rosenthal, MD |
| 11:00 AM | CON: All Patients with Pancreatic Cancer Should Undergo Open Operative
Assessment and Bypass |
Henry Pitt, MD |
| 11:15 AM | Q & A | |
| The Controversy: What is the role of MIS in the treatment of pancreatic neuroendocrine tumors? | ||
| 11:30 PM | PRO: Laparoscopic Enucleation or Resection is the treatment
of Choice for Most Pancreatic N.E. Tumors |
Quen-Jay Duh, MD |
| 11:45 PM | CON: Aggressive Open Resection and Exploration is Indicated
for Most Neuroendocrine Neoplasms |
Jeffrey Norton, MD |
| 12:00 PM | Q & A |
|
| 12:15 PM | Lunch (on your own) |
|
| The Controversy: Does laparoscopic surgery for colon cancer deliver meaningful advantages? | ||
| 1:15 PM | PRO: Results of Laparoscopic Surgery for Colorectal Cancer
Are Better Than Open Surgery |
Steven Wexner, MD |
| 1:30 PM | CON: Laparoscopic Surgery Provides No Oncologic or Perioperative
Advantages Compared to Modern Colon Surgery Techniques and Perioperative
Care |
TBA |
| The Controversy: Should curable rectal cancer be treated laparoscopically? | ||
| 1:45 PM | PRO: Laparoscopic Techniques Should Be Considered for Selected Patients
with Curable Rectal Cancer |
James Fleshman, MD |
| 2:00 PM | CON: Open TME is the Standard Treatment for All Patients with Curable
Rectal Cancer |
David Rothenberger, MD |
| 2:15 PM | Q & A |
|
| The Controversy: What is the role of surgery in the treatment of liver metastases from neuroendocrine tumors? | ||
| 2:30 PM | PRO: Metastatic Neuroendocrine Carcinoma: Aggressive Resections
are Warranted |
David Nagorny, MD |
| 2:45 PM | CON: Metastatic Neuroendocrine Carcinoma: A Conservative Multimodality Approach Is Warranted | Eugene Woltering, MD |
| 3:00 PM | Break | |
| The Controversy: What is the role of RFA in the treatment of colorectal liver metastases? | ||
| 3:15 PM | PRO: Open Resection of Liver Metastases Ensures Local Control and Survival | Steven Curley, MD |
| 3:30 PM | CON: Laparoscopic RFA of Liver Metastases Ensures Local Control and Survival | Ravi Chari, MD |
| The Controversy: What is the role of MIS resections for colorectal liver metastases? | ||
| 3:45 PM | PRO: Open Hepatic Resection is the Standard Treatment for Patients with Resectable Liver Metastases from Colorectal Cancer | Yuman Fong, MD |
| 4:00 PM | CON: MIS Hepatectomy Is Justified in Patients with Resectable Colorectal Metastases | David Geller, MD |
| 4:15 PM | Q & A | |
| The Controversy: What is the role of MIS resections for pediatric adrenal tumors? | ||
| 4:30 PM | PRO: MIS is Indicated for Pediatric Adrenal Tumors and Neuroblastoma | Andrew Davidoff, MD |
| 4:45 PM | CON: Open Surgery is Indicated for All Pediatric Adrenal Tumors | Michael LaQuaglia, MD |
| 5:00 PM | Q & A | |
| 5:15 PM | Adjourned | |
SAGES acknowledges a generous educational grant in support
of this course from:
Autosuture & Valleylab, Divisions of Tyco Healthcare
IBD Postgraduate Course
Laparoscopic Surgery for Inflammatory Bowel Disease: Technical Issues
Friday,
April 20, 2007
7:00 AM - 11:00 AM
*Included in Registration SuperPass (Option A) or Registration Option B.
Chair: Barry Salky, MD
This post-graduate course will detail the latest uses of laparoscopic techniques in the treatment of both ulcerative colitis and Crohn’s disease. The medical treatment and indications for a surgical approach will be detailed. The technical aspects of how to accomplish laparoscopic surgery in this difficult pathological group of patients will be presented. Differences in the pediatric age group will be discussed.
Objectives:
At the conclusion of this session, participants will be able to:
- Discuss how and when to recommend surgery after failed medical therapy.
- Outline the technical aspects of simple and complicated Crohn’s disease resection using laparoscopic techniques, including hand-assist surgery.
- Outline the technical aspects of total proctocolectomy with and without j-pouch in the treatment ulcerative colitis.
- Describe the different techniques required to accomplish resection in the pediatric age groups.
| Schedule | ||
|---|---|---|
| 7:00 AM | Introduction | Barry Salky, MD |
| 7:15 AM | The medical approach to Crohn’s Disease:
When is surgical treatment appropriate? |
William Faubion, MD |
| 7:32 AM | Laparoscopic Ileocecal Resection in Uncomplicated Crohn’s Disease | Anthony Senagore, MD |
| 7:49 AM | Is fistulous disease a contraindication to laparoscopic resection? Does previous open surgery make a difference? | Barry Salky, MD |
| 8:06 AM | Are there reasons to use a hand-assist technique in Crohn’s resection? | Peter Marcello, MD |
| 8:23 AM | When is laparoscopic stricturoplasty an option in Crohn’s disease? | Alessandro Fichera, MD |
| 8:40 AM | Q & A | |
| 9:00 AM | Break | |
| 9:15 AM | The Medical Approach to Ulcerative Colitis |
Thomas Ullman, MD |
| 9:32 AM | Laparoscopic Total Proctocolectomy and Standard Ileostomy | Steven Wexner, MD |
| 9:49 AM | Laparoscopic Restorative Proctocolectomy |
Tonia Young-Fadok, MD |
| 10:06 AM | Hand-Assist vs. Laparoscopic Restorative Proctocolectomy: Is there a difference in outcome? | Mark Whiteford, MD |
| 10:23 AM | Indications for Surgery in the Pediatric Population |
Marc Levitt, MD |
| 10:40 AM | Q & A | |
SAGES acknowledges a generous educational grant in support of this course from: Centocor